MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The first results of Anti-Vascular Endothelial Growth Factor (VEGF) therapy were very promising and superior to established therapies. Three different substances (all of them applied intravitreally) are available, but comparative studies have not yet been conducted. In this pilot study, the safety (number of adverse events) and efficacy (distance acuity testing retinal thickness measurement) of Avastin and Macugen applied as monotherapy will be compared to a combined treatment of Avastin followed by Macugen used for retreatment.

At least equal results of the combined therapy are expected.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Age > 50 years

• Predominantly occult CNV

• Greatest diameter of the lesion < 5400µm

• Distance acuity > 0.1

Exclusion Criteria:

• Complicating general disorders inflicting with healing process

• Vision threatening diseases other than CNV

• Prior treatment for CNV

• Ophthalmic surgery within 4 weeks

• Not consented patients